Yahoo
NasdaqGM - Delayed Quote USD

Pharming Group N.V. (PHAR)

11.83 -0.40 (-3.27%)
At close: August 12 at 4:00:00 PM EDT
12.20 +0.37 (+3.13%)
Pre-Market: 4:06:06 AM EDT
Trade PHAR on Coinbase
Chart Range Bar
Loading chart for PHAR
  • Previous Close 12.23
  • Open 11.81
  • Bid 17.34 x 100
  • Ask 12.17 x 100
  • Day's Range 11.66 - 12.13
  • 52 Week Range 9.62 - 21.34
  • Volume 38,277
  • Avg. Volume 12,032
  • Market Cap (intraday) 837.305M
  • Beta (5Y Monthly) 0.06
  • PE Ratio (TTM) 84.50
  • EPS (TTM) 0.14
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 34.35

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

www.pharming.com

407

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 8/13/2026, which may include dividends or other distributions. Benchmark is AEX-Index (^AEX) .

YTD Return

PHAR
29.63%
AEX-Index (^AEX)
17.46%

1-Year Return

PHAR
4.69%
AEX-Index (^AEX)
24.14%

3-Year Return

PHAR
4.60%
AEX-Index (^AEX)
46.04%

5-Year Return

PHAR
13.21%
AEX-Index (^AEX)
44.21%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 90.21M
Earnings 1.64M

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
20M
40M
60M
80M
100M

Analyst Insights

View More

Analyst Price Targets

23.40
34.35 Average
11.83 Current
39.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/3/2026
Analyst Canaccord Genuity
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 37 -> 38

Statistics

View More

Valuation Measures

Annual
As of 8/10/2026
  • Market Cap

    777.83M

  • Enterprise Value

    732.84M

  • Trailing P/E

    81.07

  • Forward P/E

    263.16

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.32

  • Price/Book (mrq)

    2.97

  • Enterprise Value/Revenue

    2.00

  • Enterprise Value/EBITDA

    18.83

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    2.54%

  • Return on Assets (ttm)

    3.47%

  • Return on Equity (ttm)

    3.65%

  • Revenue (ttm)

    366.48M

  • Net Income Avi to Common (ttm)

    9.3M

  • Diluted EPS (ttm)

    0.14

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    158.28M

  • Total Debt/Equity (mrq)

    41.88%

  • Levered Free Cash Flow (ttm)

    37.69M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

11.83 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: